Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 9 - Drugs for disorders of the cardiovascular system
Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484)
04/2003
04/01/2003US6541522 Including longistyline A-2-carboxylic acid as a dietary supplement
04/01/2003US6541511 Treatment and prophylaxis of hypercholesterolemia and of various cardiac disorders.
04/01/2003US6541505 Inhibiting the activity of Factor Xa; treating a disease state associated with a physiologically detrimental excess amount of thrombin.
04/01/2003US6541503 Substituted oxindole derivatives as protein tyrosine kinase and as protein serine/threonine kinase inhibitors
04/01/2003US6541496 Inhibitors of IMPDH enzyme
04/01/2003US6541492 Thiazole derivatives as PPAR gamma ligands
04/01/2003US6541490 Treating ischemia or reoxygenation injury; preparation from a bipyridine, a benzeneboronic acid and a manganese salt
04/01/2003US6541489 Excellent inhibitory activity of one or more matrix metalloprotease (MMP) enzymes, such as MMP-2, MMP-9, and MMP-13, while exhibiting substantially less inhibition at least of MMP- 1
04/01/2003US6541488 Compositions for treating arterial thrombosis and a factor Xa inhibitor
04/01/2003US6541486 Used for treating ischemia, such as results from stroke or myocardial infarction, trauma, neurodegeneration, and inflammation.
04/01/2003US6541482 Autoimmune disease
04/01/2003US6541475 2-nitrostyryl-1-(naphthylmethyl)sulfone for example
04/01/2003US6541471 Useful as a TXA2 receptor antagonist and a 5-HT2 receptor antagonist
04/01/2003US6541469 CRF receptor antagonists and methods relating thereto
04/01/2003US6541457 Mammalian IAP gene family, primers, probes and detection methods
04/01/2003US6541015 Water soluble prodrug with a biologically active agent link trapped in a hydrogel and controllably released by diffusion
04/01/2003US6541008 Vascular endothelial growth factor-like protein from orf viruses binds and activates mammalian VEGF receptor-2, and uses thereof
04/01/2003CA2163539C N-morpholino-n-nitrosaminoacetonitrile cyclodextrin inclusion complexes
04/01/2003CA2102129C Growth hormone antagonists
03/2003
03/31/2003WO2002030425A1 Preventives and remedies for complications of diabetes
03/31/2003CA2424060A1 Preventives and remedies for complications of diabetes
03/28/2003CA2404045A1 Use of coagulation factor vii-activating protease for the prophylaxis and therapy of vasoproliferative disorders
03/27/2003WO2003025579A2 Use of heart fatty acid binding protein
03/27/2003WO2003025542A2 Immune response associated proteins
03/27/2003WO2003025199A2 Mid 4460, a human tyrosine phosphatase family member and uses therefor
03/27/2003WO2003025168A1 Novel protein and dna thereof
03/27/2003WO2003025162A2 Regulation of human prolyl 4-hydroxylase alpha subunit precursor
03/27/2003WO2003025149A2 Cell populations which co-express cd49c and cd90
03/27/2003WO2003025131A2 Protein modification and maintenance molecules
03/27/2003WO2003025129A2 Neurotransmission-associated proteins
03/27/2003WO2003025121A2 Igf-binding protein-derived peptide or small molecule
03/27/2003WO2003024973A1 Spirocyclic-6,7-dihydro-5h-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines
03/27/2003WO2003024971A1 6,7-dihydro-5h-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines
03/27/2003WO2003024970A1 Compounds which inhibit the release of inflammatory cytokines
03/27/2003WO2003024969A1 Tyrosine kinase inhibitors
03/27/2003WO2003024966A1 Pteridinone derivatives as modulators of chemokine receptor activity
03/27/2003WO2003024956A1 Method for preparing pyrimidinone compound and pharmaceutically acceptable salts thereof
03/27/2003WO2003024949A1 Dna-pk inhibitors
03/27/2003WO2003024948A1 Benzofuran and dihydrobenzofuran derivatives useful as beta-3 adrenoreceptor agonists
03/27/2003WO2003024946A2 Oxamate derivatives containing a variously substituted nitrogen heterocycle
03/27/2003WO2003024937A1 Benzimidazolylalkoxyaryl alkanoic acid derivatives and their use as antihyperglycemics
03/27/2003WO2003024928A2 Novel aminoazetidine, -pyrrolidine and -piperidine derivatives
03/27/2003WO2003024922A1 Hydroxyfattysulfonic acid analogs
03/27/2003WO2003024913A1 SUBSTITUTED BENZOIC ACID DERIVATIVES EXHIBITING NF-κB INHIBITING ACTIVITY
03/27/2003WO2003024485A1 REMEDIES FOR DISEASES CAUSED BY β-AMYLOIDS CONTAINING 2-100β INHIBITOR AS THE ACTIVE INGREDIENT
03/27/2003WO2003024479A1 Enamel matrix protein compositions for modulating immune response
03/27/2003WO2003024457A1 Medicinal composition for prevention of or treatment for cerebrovascular disorder and cardiopathy
03/27/2003WO2003024446A1 Oxidation stress inhibitor and method of measuring oxidation stress
03/27/2003WO2003024445A1 Drugs comprising combination of antithrombotic agent with pyrazolone derivative
03/27/2003WO2003024441A1 Novel use of tricyclic compound
03/27/2003WO2003024440A1 Salicylic acid salts, methods for the production and use thereof as medicaments
03/27/2003WO2003024439A1 Phenethanolamine derivatives for treatment of respiratory diseases
03/27/2003WO2003024423A1 Apoptosis-mimicking synthetic entities and use thereof in medical treatment
03/27/2003WO2003024402A2 Lpa receptor agonists and antagonists and methods of use
03/27/2003WO2003024395A2 Linked biaryl compounds
03/27/2003WO2003024390A2 Hydroxyeicosenoic acid analogs
03/27/2003WO2003024237A1 Oil composition
03/27/2003WO2003002553A3 Fluoropyrrolidines as dipeptidyl peptidase inhibitors
03/27/2003WO2003002058A8 Bone anabolic compounds and methods of use
03/27/2003WO2002098356A3 Ppp2cs as modifiers of the p53 pathway and methods of use
03/27/2003WO2002096358A3 Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method
03/27/2003WO2002094263A3 Caspase inhibitors and uses thereof
03/27/2003WO2002094019A9 Highly purified antiendotoxin compound
03/27/2003WO2002089781A3 Methods of treating hyperlipidemia
03/27/2003WO2002087496A3 Methods for inhibiting macrophage colony stimulating factor and c-fms-dependent cell signaling
03/27/2003WO2002083870A3 Pufa polyketide synthase systems and uses thereof
03/27/2003WO2002060859A3 Cyclic derivatives as modulators of chemokine receptor activity
03/27/2003WO2002056941A3 Method for the treatment of peripheral vascular disease
03/27/2003WO2002055544A3 Fibrin binding polypeptides useful inter alia in medical imaging processes
03/27/2003WO2002053717A3 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
03/27/2003WO2002053100A3 Pharmaceutical dosage form for oral administration of low molecular weight heparin
03/27/2003WO2002048358A3 Regulation of human chemokine-like receptor
03/27/2003WO2002047680A3 Use of tocopherol, metabolites or derivatives thereof or flavonoid metabolites or derivatives thereof in the manufacture of a medicament for the treatment of tissue ischemia
03/27/2003WO2002043806A3 In vivo delivery methods and compositions
03/27/2003WO2002028844A1 Thiazole or oxazole derivatives
03/27/2003WO2002026774A3 Melanocortin receptor ligands
03/27/2003WO2002017880A3 Nitric oxide-producing hydrogel materials
03/27/2003WO2002016585A3 Imidazoline receptor homologs
03/27/2003WO2002016419A9 Progression suppressed gene 13 (psgen 13) and uses thereof
03/27/2003WO2002012340A3 Transporters and ion channels
03/27/2003WO2001092218A3 Polyamine analogues as therapeutic and diagnostic agents
03/27/2003WO2001062954A3 Stearoyl-coa desaturase to identify triglyceride reducing therapeutic agents
03/27/2003US20030060877 Coated medical devices for the treatment of vascular disease
03/27/2003US20030060873 Providing an electrochemical solution comprising metal and bioactive material; contacting electrochemical solution and substrate; forming a bioactive composite structure on substrate using an electrochemical procedure
03/27/2003US20030060629 Pyrazine derivatives as modulators of tyrosine kinases
03/27/2003US20030060627 8-Phenyl-6, 9-dihydro-[1,2,4] triazolo[3,4-i]purin-5-one derivatives
03/27/2003US20030060624 Reacting 2-chloro-4- trifluoromethyl-phenyl)-acetonitrile in the presence of a palladium catalyst and a base to form indene derivative
03/27/2003US20030060619 Antibody for use in the disgnosis and treatment of kidney, urogenital, and sex disorders
03/27/2003US20030060604 Apolipoprotein agonist for use in the treatment of dyslipidemia
03/27/2003US20030060497 Use of indole Mannich bases in the production of medicaments that are used to treat pain
03/27/2003US20030060493 Kit comprising a pharmaceutical composition containing repinotan or a physiologically acceptable salt of repinotan, and a means for the determination of the concentration of repinotan or its metabolites in body
03/27/2003US20030060487 Useful for treatments for peptide aggregation associated with disease state such as Alzhemimer's diseases
03/27/2003US20030060477 Administering to a patient a betablocker and a cholesterol-lowering agent to treat atherosclerosis, hyperpoproteinemia and hypercholesterolemia
03/27/2003US20030060470 Ortho, ortho-substituted nitrogen-containing bisaryl compounds, processes for their preparation, their use as medicaments, and pharmaceutical preparation comprising them
03/27/2003US20030060466 Such as 6-(4-(4-Fluoro-phenyl)-piperazin-1-yl)-2-methyl-5-nitro-3-(2,2,2-trifluoro -ethyl)-3H-pyrimidin-4-one, which are metabotropic glutamate receptor antagonists useful in treating psychological disorders
03/27/2003US20030060462 Therapeutic compounds
03/27/2003US20030060461 Cyclic diamine compound with condensed-ring groups
03/27/2003US20030060459 Diamines as modulators of chemokine receptor activity
03/27/2003US20030060455 Treating lung damage from smoke, endometriosis, Behcet's disease, ankylosing spondylitis, cancer, Lyme disease, and/or restenosis following agioplasty with 1-(4-t-butyl-phenyl)-3-(4-(6-morpholin-4-ylmethyl-peperidin-yl)naphthalen-1 -yl)-urea
03/27/2003US20030060452 N-heterocyclic derivatives as NOS inhibitors
1 ... 1028 1029 1030 1031 1032 1033 1034 1035 1036 1037 1038 1039 1040 1041 1042 1043 1044 1045 1046 1047 1048 ... 1595